User: Guest  Login
Title:

Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond.

Document type:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Author(s):
Lukowski, Robert; Krieg, Thomas; Rybalkin, Sergei D; Beavo, Joseph; Hofmann, Franz
Abstract:
cGMP inhibits hypertrophy, decreases fibrosis, and protects against cardiac ischemia-reperfusion (I/R) injury. Gene-targeting studies have not defined a clear role for its major downstream effector, cGMP-dependent protein kinase I (cGKI), in cardiac hypertrophy, but do implicate cGMP-cGKI signaling in fibrosis and I/R injury. No direct cGKI activators have advanced to clinical trials, whereas cardiac trials of agents that modulate cGMP via particulate or soluble guanylyl cyclases (GCs) and phosp...     »
Journal title abbreviation:
Trends Pharmacol Sci
Year:
2014
Journal volume:
35
Journal issue:
8
Pages contribution:
404-13
Language:
eng
Fulltext / DOI:
doi:10.1016/j.tips.2014.05.003
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/24948380
Print-ISSN:
0165-6147
TUM Institution:
Institut für Pharmakologie und Toxikologie
 BibTeX